Eli Lilly and Company (BVMF:LILY34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 3.81T -1.6% |
| Revenue (ttm) | 359.01B +44.7% |
| Net Income | 113.69B +94.9% |
| EPS | 126.41 +96.0% |
| Shares Out | n/a |
| PE Ratio | 33.52 |
| Forward PE | 24.70 |
| Dividend | 0.75 (0.53%) |
| Ex-Dividend Date | Feb 12, 2026 |
| Volume | 6,514 |
| Average Volume | 11,971 |
| Open | 145.40 |
| Previous Close | 145.40 |
| Day's Range | 142.00 - 145.40 |
| 52-Week Range | 113.00 - 208.36 |
| Beta | 0.50 |
| RSI | 30.00 |
| Earnings Date | Apr 30, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Eli Lilly stock jumps 6% after strong earnings and raised guidance
Eli Lilly reported stronger-than-expected first-quarter earnings and revenue on Thursday, driven by robust demand for its blockbuster weight-loss and diabetes drugs, prompting the company to raise its...
Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket
Revenue tied to Lilly's Zepbound and Mounjaro more than doubles from the same period last year.
Lilly's stock rallies as sales of GLP-1 drugs nearly double
Sales of Mounjaro and Zepbound both beat expectations
Eli Lilly raises annual profit forecast as GLP-1 drugs fuel growth
Eli Lilly raised its annual profit forecast and posted better-than-expected first quarter on Thursday, on steady demand for its weight-loss and diabetes drugs Zepbound and Mounjaro, in its first res...
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines
Revenue in Q1 2026 increased 56% to $19.8 billion primarily driven by volume growth, partially offset by lower realized prices from Mounjaro and Zepbound. Q1 2026 EPS increased by 170% to $8.26 on a r...
Eli Lilly will report first quarter earnings before the bell. Here's what Wall Street expects
Eli Lilly is slated to report first-quarter earnings before the bell on Thursday, in one of the most closely watched reports across the healthcare sector. The company's newly approved GLP-1 pill for o...
Eli Lilly Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Eli Lilly and Company (NYSE:LLY) will release earnings for its first quarter before the opening bell on Thursday, April 30.
Here's How Much Traders Expect Eli Lilly Stock To Move After Earnings
Eli Lilly is scheduled to report its latest quarterly earnings ahead of the opening bell Thursday, with shares seen potentially falling to their lowest level in months following the report.
Eli Lilly investors are eager for Foundayo insight after early launch data
Eli Lilly investors will be searching for something they won't find in any first-quarter financial figures reported on Thursday: insight into the launch of weight-loss pill Foundayo.
Profluent, Lilly partner in genetic medicine deal worth up to $2.25 billion
AI firm Profluent said on Tuesday it has struck a multi-program research collaboration with U.S. drugmaker Eli Lilly worth up to $2.25 billion to develop AI-designed enzymes for genetic ...
Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial
Boehringer Ingelheim said on Tuesday its experimental obesity drug led to average weight loss of up to 16.6% in a late-stage trial, as the unlisted German drugmaker seeks to catch up with obesity dr...
Pharma bets a little-known cholesterol will underpin its next blockbuster heart drugs
Novartis, Amgen and Eli Lilly are among the pharmaceutical companies developing drugs to lower levels of a particularly bad form of cholesterol called Lp(a) and potentially prevent heart attacks. Lp(a...
As Investors Focus on Lilly's Foundayo, They May Be Overlooking Another Key Catalyst
Eli Lilly's Foundayo launch is drawing attention, but analysts say eloralintide and combination therapies could drive the next leg of growth.
Eli Lilly to Buy Ajax Therapeutics for Up to $2.3 Billion
Eli Lilly continued its recent buying spree, agreeing to pay up to $2.3 billion for Ajax Therapeutics in a deal that bolsters the drugmaker's blood-cancer portfolio.
Eli Lilly to acquire Ajax Therapeutics for up to $2.3 billion
Eli Lilly said on Monday it would buy privately-held blood cancer treatment developer Ajax Therapeutics for up to $2.3 billion in cash.
Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026 Based on i...
Lilly stock falls as Foundayo trails Novo's Wegovy in early uptake
Shares of Eli Lilly came under pressure on Friday after early prescription data for its newly launched weight-loss pill suggested a slower rollout compared with rival Novo Nordisk's competing product....
Lilly's obesity pill hits nearly 4000 prescriptions in second week after launch
Eli Lilly's newly launched oral weight loss drug was prescribed 3,707 times in the U.S. in the second week after its launch earlier this month, according to analysts citing IQVIA data.
‘BUYING OPPORTUNITIES': Investor reveals TOP stock picks amid uncertainty
BD8 Capital Partners CIO Barbara Doran discusses the market's rebound and retail investor re-entry on ‘Making Money.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #makingmoney ...
Eli Lilly Is More Than GLP-1 Drugs. The Stock Looks Attractive.
The acquisition of Kelonia Therapeutics, announced this week, is part of Lilly's expansion into cancer treatments.
Health insurers raise questions about Medicare program that will offer GLP-1s to seniors for $50
Some health insurers are pushing back against a new program that will allow Medicare beneficiaries to pay $50 per month for GLP-1 medications for weight loss.
Monday's Final Takeaways: LLY New Acquisition & AAL Shuts Down UAL Bid
Eli Lilly's (LLY) $7 billion acquisition of Kelonia Therapeutics and American Airlines (AAL) denying a United Airlines (UAL) acquisition bid take Sam Vadas and Marley Kayden's attention for Monday's f...
Eli Lilly Goes Atomic—But This Isn't About AI Servers
The drugmaker behind Prozac and Cialis is now exploring nuclear energy, signing a letter of intent with Indiana to support small modular reactors and advanced nuclear tech. The signal here isn't about...
Eli Lilly to buy Kelonia Therapeutics in up to $7 billion cancer immunotherapy drug deal
CNBC's Angelica Peebles reports the latest news on pharmaceuticals.
Eli Lilly to acquire Kelonia in $7 billion cancer therapy push
Eli Lilly said on Monday it will acquire privately held Kelonia Therapeutics in a deal worth up to $7 billion, as the drugmaker deepens its presence in next-generation cancer treatments. The agreement...